Lee Pharma
Founded in 1997, Lee Pharma Limited is a research-driven pharmaceutical company that develops and manufactures active pharmaceutical ingredients (APIs), intermediates, semi-finished dosage forms (pellets & granules) and finished oral solid formulations. The company operates certified manufacturing and R&D facilities and provides contract development and manufacturing services to global markets.
Industries
Nr. of Employees
large (251-1000)
Lee Pharma
SY. No. : 257 & 258/1, Door No: 11-6/56-C, Opp: IDPL Factory, Moosapet, Balanagar (Post), Hyderabad – 500 037, India.
Patents
Products
Sitagliptin phosphate monohydrate (API and tablets)
DPP-4 inhibitor API and tablet formulations; development and dossier activity noted for multiple strengths.
Rosuvastatin calcium (API)
Statin-class API available in multiple pharmacopeial grades with DMF/USDMF activity.
Pellets and granules (enteric, immediate, sustained)
Multiple pellet and granule formulations for use in tablets, capsules and oral suspensions, including enteric-coated and sustained-release variants.
Sitagliptin phosphate monohydrate (API and tablets)
DPP-4 inhibitor API and tablet formulations; development and dossier activity noted for multiple strengths.
Rosuvastatin calcium (API)
Statin-class API available in multiple pharmacopeial grades with DMF/USDMF activity.
Pellets and granules (enteric, immediate, sustained)
Multiple pellet and granule formulations for use in tablets, capsules and oral suspensions, including enteric-coated and sustained-release variants.
Services
End-to-end contract services including custom synthesis, formulation development, tech-pack/dossier preparation, technology transfer and commercial manufacturing.
Development, registration support and commercial supply of small-molecule APIs across multiple therapeutic areas with DMF/CEP filing activity.
Formulation development for immediate- and modified-release oral solids, pilot/scale manufacturing of tablets and capsules and packaging development.
Analytical development for compound characterization, impurity identification/isolation and control strategies including genotoxic and nitrosamine impurity evaluation.
End-to-end contract services including custom synthesis, formulation development, tech-pack/dossier preparation, technology transfer and commercial manufacturing.
Development, registration support and commercial supply of small-molecule APIs across multiple therapeutic areas with DMF/CEP filing activity.
Formulation development for immediate- and modified-release oral solids, pilot/scale manufacturing of tablets and capsules and packaging development.
Analytical development for compound characterization, impurity identification/isolation and control strategies including genotoxic and nitrosamine impurity evaluation.
Expertise Areas
- API development and manufacturing
- Formulation development for oral solid dosage forms
- Pellets and granules technologies (enteric, immediate, sustained)
- Modified-release drug delivery
Key Technologies
- Pelletization and granulation
- Multiple Unit Pellet System (MUPS)
- Direct compression (DC) granules
- Enteric-coated and delayed-release technologies
News & Updates
Sustainability report documenting the company’s ESG practices, performance and alignment with global frameworks.
Granted patents include processes for Linezolid and related intermediates (granted US and EP patents listed).
Sustainability report documenting the company’s ESG practices, performance and alignment with global frameworks.
Granted patents include processes for Linezolid and related intermediates (granted US and EP patents listed).